JP2023527542A - コレステロール関連障害を治療するためのpcsk9阻害剤及びその使用の方法 - Google Patents

コレステロール関連障害を治療するためのpcsk9阻害剤及びその使用の方法 Download PDF

Info

Publication number
JP2023527542A
JP2023527542A JP2022573247A JP2022573247A JP2023527542A JP 2023527542 A JP2023527542 A JP 2023527542A JP 2022573247 A JP2022573247 A JP 2022573247A JP 2022573247 A JP2022573247 A JP 2022573247A JP 2023527542 A JP2023527542 A JP 2023527542A
Authority
JP
Japan
Prior art keywords
ldl
subject
pcsk9
hefh
pediatric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527542A5 (cg-RX-API-DMAC7.html
Inventor
ヘイマー,アンドルー・ダブリュ
ブリッジズ,イアン・マシュー
ワン,フイ
ルッツァ,アンドレア
カーツ,クリストファー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2023527542A publication Critical patent/JP2023527542A/ja
Publication of JP2023527542A5 publication Critical patent/JP2023527542A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2022573247A 2020-05-29 2021-05-27 コレステロール関連障害を治療するためのpcsk9阻害剤及びその使用の方法 Pending JP2023527542A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032451P 2020-05-29 2020-05-29
US63/032,451 2020-05-29
PCT/US2021/034489 WO2021243002A1 (en) 2020-05-29 2021-05-27 Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders

Publications (2)

Publication Number Publication Date
JP2023527542A true JP2023527542A (ja) 2023-06-29
JP2023527542A5 JP2023527542A5 (cg-RX-API-DMAC7.html) 2024-06-03

Family

ID=78722769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573247A Pending JP2023527542A (ja) 2020-05-29 2021-05-27 コレステロール関連障害を治療するためのpcsk9阻害剤及びその使用の方法

Country Status (11)

Country Link
US (1) US20230235085A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157887A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023527542A (cg-RX-API-DMAC7.html)
CN (1) CN115916838A (cg-RX-API-DMAC7.html)
AR (1) AR122180A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021281256A1 (cg-RX-API-DMAC7.html)
CA (1) CA3179316A1 (cg-RX-API-DMAC7.html)
IL (1) IL298375A (cg-RX-API-DMAC7.html)
JO (1) JOP20220322A1 (cg-RX-API-DMAC7.html)
TW (1) TW202210524A (cg-RX-API-DMAC7.html)
WO (1) WO2021243002A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
WO2025036347A1 (zh) 2023-08-14 2025-02-20 信立泰(成都)生物技术有限公司 Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
WO2025265012A1 (en) * 2024-06-21 2025-12-26 Amgen Inc. Compositions comprising anti-pcsk9 antbodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
KR20230074283A (ko) * 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JACC, vol. 75, no. 6, JPN6025021741, 18 February 2020 (2020-02-18), pages 565 - 574, ISSN: 0005834006 *
JOURNAL OF CLINICAL LIPIDOLOGY, vol. 14, JPN6025021742, 28 March 2020 (2020-03-28), pages 322 - 330, ISSN: 0005834007 *
NEJM, vol. 383, no. 14, JPN6025021743, 1 October 2020 (2020-10-01), pages 1317 - 1327, ISSN: 0005609058 *

Also Published As

Publication number Publication date
US20230235085A1 (en) 2023-07-27
CN115916838A (zh) 2023-04-04
EP4157887A4 (en) 2024-07-03
JOP20220322A1 (ar) 2022-11-27
TW202210524A (zh) 2022-03-16
CA3179316A1 (en) 2021-12-02
EP4157887A1 (en) 2023-04-05
AU2021281256A1 (en) 2022-12-22
AR122180A1 (es) 2022-08-24
IL298375A (en) 2023-01-01
WO2021243002A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
US12331122B2 (en) Anti-ASGR-1 monoclonal inhibitory antibodies
EP2074149B1 (en) Compositions and methods relating to glucagon receptor antibodies
US20230235085A1 (en) Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders
EP4283295A2 (en) Recombinant polyclonal proteins and methods of use thereof
KR20220004985A (ko) Cd40 활성화 특성을 가진 재조합 단백질
JP7558949B2 (ja) 抗ctla-4結合タンパク質およびその使用方法
US20220064268A1 (en) Recombinant polyclonal proteins targeting zika and methods of use thereof
US20220041715A1 (en) Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
US20230265192A1 (en) Anti-ctla-4 binding proteins and methods of use thereof
US20120269814A1 (en) Anti-c mpl antibodies
WO2020142626A1 (en) Anti-ox40 binding proteins and methods of use thereof
WO2020140070A1 (en) Anti-b7-h4 binding proteins and methods of use thereof
HK40090853A (en) Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders
US20250289903A1 (en) Methods and compositions for treating eosinophil driven diseases and disorders
TW202323300A (zh) 抗tigit構築體及其用途
TW202228768A (zh) 用於治療疼痛之化合物及方法
JP2023525140A (ja) Ox40活性化特性を有する組換えタンパク質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240524

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260807